Stockscreener 앱 받기
13.43
0.07%
-0.010
전일 마감가:
$13.44
열려 있는:
$13.59
하루 거래량:
190.84K
Relative Volume:
0.99
시가총액:
$592.53M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+9.01%
1개월 성능:
+34.30%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$13.35
$14.50
1주일 범위
$11.77
$14.50
52주 변동 폭
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
명칭
Sionna Therapeutics Inc
전화
617-819-2020
주소
21 HICKORY DRIVE, SUITE 500, WALTHAM
SION을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
13.43 | 543.61M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-04 | 개시 | Guggenheim | Buy |
| 2025-03-04 | 개시 | Stifel | Buy |
| 2025-03-04 | 개시 | TD Cowen | Buy |
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Weak Earnings - Defense World
Sionna Therapeutics Phase 1 Topline Data For Nbd1 Stabilizers Sion-719 & Sion-451 Expected This Quarter - marketscreener.com
Sionna Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Private equity firms invested in Sionna Therapeutics, Inc. (NASDAQ:SION) copped the brunt of last week's US$56m market cap decline - simplywall.st
While individual investors own 26% of Sionna Therapeutics, Inc. (NASDAQ:SION), private equity firms are its largest shareholders with 56% ownership - Yahoo Finance
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 - The Manila Times
Revolutionary Cystic Fibrosis Treatment Developer Sionna Takes Stage at Major Healthcare Conference - Stock Titan
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
SIONSionna Therapeutics Latest Stock News & Market Updates - StockTitan
Pre-market Movers: REVB, QSI, EYEN, NAOV ... - RTTNews
Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Sionna Therapeutics, Inc.’s Quiet Period To Expire on March 19th (NASDAQ:SION) - Defense World
February financings slowing, but year outpaces 2022-2023 - BioWorld Online
Guggenheim Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Investorideas.com adds New IPOs in Biotech, Technology, Homebuilder, Aerospace, Sports - Investorideas.com newswire
Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Stifel Nicolaus Initiates Coverage on Sionna Therapeutics (NASDAQ:SION) - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics (NASDAQ:SION) Now Covered by Stifel Nicolaus - MarketBeat
TD Cowen Initiates Sionna Therapeutics at Buy -March 04, 2025 at 07:57 am EST - Marketscreener.com
Guggenheim Initiates Sionna Therapeutics at Buy With $45 Price Target -March 04, 2025 at 07:58 am EST - Marketscreener.com
Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target -March 04, 2025 at 07:57 am EST - Marketscreener.com
TD Cowen initiates Sionna Therapeutics stock with Buy rating By Investing.com - Investing.com UK
Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation - TipRanks
Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market - TipRanks
Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating - TipRanks
Guggenheim sets Sionna stock Buy rating, $45 target By Investing.com - Investing.com Canada
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
Sionna Therapeutics’ NBD1 stabilizers hold potential for cystic fibrosis - The Pharma Letter
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market - Yahoo Finance
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference - The Manila Times
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Sionna Therapeutics Inc 주식 (SION) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
1.54%
7.58%
자본화:
|
볼륨(24시간):